In this article, we will list the 5 Cheap Robotics Stocks to Buy Right Now. Please visit 10 Cheap Robotics Stocks to Buy Right Now if you would like to see the extended list and the methodology behind it.
5. Aptiv PLC (NYSE:APTV)
Stock Upside Potential: 30.11%
Forward P/E: 9.36
Number of Hedge Fund Holders: 53
Aptiv PLC (NYSE:APTV) is one of the cheap robotics stocks to buy right now. On May 6, UBS reiterated a Buy rating on Aptiv PLC (NYSE:APTV) and an $80 price target, buoyed by the company’s solid first-quarter results.
The better-than-expected results came as the company increasingly focuses on enabling devices and systems that sense, think, act, and optimize across all industries. The company delivered a 5% year-over-year increase in revenue to $5.1 billion, driven by 7% growth in North America and 7% growth in South America.
Aptiv PLC also bounced back to profitability, reporting net income of $189 million and earnings per share of $0.88, compared with a net loss of $11 million, or $0.05 a share, delivered in the same quarter last year. For the second quarter, the company expects net sales to range between $3.2 billion and $3.4 billion with net income of between $140 million and $180 million. For the full year, sales are expected to be between $12.8 billion and $13.2 billion, with net income between $830 and $910 million.
According to UBS, Aptiv is well-positioned to meet its guidance and maintain its outlook despite cost pressures. The research firm also sees positive developments in China.
Aptiv PLC (NYSE:APTV) is a global technology company that designs, develops, and manufactures hardware and software solutions for the automotive and commercial vehicle industries.
4. Medtronic plc (NYSE:MDT)
Stock upside Potential: 38.04%
Forward P/E: 12.49
Number of Hedge Fund Holders: 60
Medtronic plc (NYSE:MDT) is one of the cheap robotics stocks to buy right now. On May 20, Medtronic PLC (NYSE:MDT) reiterated plans to expand its care options for people struggling with chronic pain with the acquisition of SPR Therapeutics.
The company is poised to pay $650 million to acquire all outstanding equity in SPR, underscoring its focus on deals that enhance its core franchises. The transaction is poised to close in the fall, within the first half of Medtronic’s Fiscal Year 2027, subject to regulatory approvals.
The acquisition will enhance the company’s Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology. Consequently, it will be well equipped to reach and support people with minimally invasive pain-relief options.
Medtronic is to gain access to SPR’s SPRINT System, which provides pain relief without the need for permanent implants. In addition, the acquisition will enable the company to reach more patients with less-invasive pain relief solutions.
“Our purpose first and foremost is to serve patients,” said Domenico De Paolis, Interim President, Neuromodulation, part of the Medtronic Neuroscience Portfolio. “That is why we continue to thoughtfully expand our pain intervention therapies. The addition of temporary peripheral nerve stimulation helps broaden access to neuromodulation and supports patients across more stages of the chronic pain journey with a minimally invasive therapy.”
On March 27, Medtronic received FDA clearance for its Stealth AXiS surgical system for cranial and ENT procedures, following earlier approval for spine. The platform unifies planning, navigation, and robotics into one intelligent system, offering AI‑enabled tractography for brain mapping, real‑time imaging through GE HealthCare’s bkActiv, and advanced visualization tailored to ENT workflows. Designed with flexible architecture to support ongoing innovation, Stealth AXiS reinforces Medtronic’s strategy to deliver connected technologies that enhance precision, efficiency, and surgeon confidence across multiple specialties.
Medtronic plc (NYSE:MDT) develops advanced robotic-assisted surgery (RAS) platforms and AI-driven surgical technologies designed to increase precision, reduce hospital stays, and lower healthcare costs. Their robotics portfolio spans multiple medical specialties, most notably soft-tissue surgery, spine procedures, and cranial care.
3. Stryker Corporation (NYSE:SYK)
Stock Upside Potential: 28.02%
Forward P/E: 18.38
Number of Hedge Fund Holders: 81
Stryker Corporation (NYSE:SYK) is one of the cheap robotics stocks to buy right now. On May 26, Stryker Corporation (NYSE:SYK) launched its Pangea Plating System platform in Europe for the treatment of fracture patterns. The launch follows the completion of the first clinical case in Europe.
The Pangea Plating System features non-active implants that provide temporary stabilization of bones or bone fragments. It also features plates and complementary instrumentation that support plate fit, providing surgeons with options for fracture fixation.
The fracture pattern system was developed in collaboration with 26 orthopedic surgeons. It is now part of Stryker’s Pangea portfolio, which incorporates global anatomical data to support plate fixation across patients. Its development underscores the company’s focus and bid in developing solutions that enhance surgical workflow and address evolving needs in trauma care.
Pangea Plating System’s European launch is poised to expand Stryker’s trauma portfolio while underscoring the company’s commitment to supporting fracture fixation in collaboration with orthopedic surgeons worldwide.
In February 2026, Stryker announced the limited release of Mako RPS (Robotic Power System) for Total Knee, a handheld robotic system that combines its robotics and power tool expertise. Compatible with the Triathlon Total Knee System, Mako RPS offers surgeons robotic precision with the familiarity of manual tools, featuring intraoperative planning and an active‑adjustment saw that guides movements in real time.
Building on nearly 20 years of Orthopaedic robotics and over 2 million procedures worldwide, Stryker has expanded the Mako brand to include both Mako SmartRobotics and Mako Handheld Robotics, reinforcing its leadership in advancing patient outcomes.
Stryker Corporation (NYSE:SYK) is a leading global medical technology company that manufactures and supplies innovative surgical equipment, medical devices, and implantable products. Their technologies are used by hospitals and healthcare facilities globally to improve patient outcomes and streamline surgical procedures.
2. Johnson & Johnson (NYSE:JNJ)
Stock Upside Potential: 15.47%
Forward P/E: 18.09
Number of Hedge Fund Holders: 113
Johnson & Johnson (NYSE:JNJ) is one of the cheap robotics stocks to buy right now. On May 12, Johnson & Johnson (NYSE:JNJ) confirmed the global launch of the Shockwave C2 Aero Coronary IVL Catheter for the treatment of calcified coronary artery disease, as it seeks to redefine the standards of coronary IVL with efficient, predictable procedures.
The next-generation intravascular lithotripsy catheter features enhanced deliverability and lesion-crossing capabilities. It leverages ultrasonic acoustic pressure waves to disrupt calcified plaque in coronary arteries, extending Shockwave IVL’s clinically validated mechanism of action. It also features a flexible shaft balloon and marker brands to enhance navigation in tortuous arteries.
The Shockwave C2 Aero Coronary IVL Catheter enables Johnson & Johnson to target the 315 million people worldwide who are struggling with coronary artery disease. The company has already made the device available in the US and Japan. It also plans to make it available in Europe and Canada.
Earlier on May 5, Johnson & Johnson announced results from the first clinical study of its investigational OTTAVA Robotic Surgical System, showing that in a 30‑patient trial for Roux‑en‑Y gastric bypass all procedures were completed robotically without conversion, meeting safety and performance endpoints and achieving an average 30‑pound weight loss at 30 days.
The data, presented at the 2026 ASMBS Annual Meeting, supported an FDA De Novo application for OTTAVA to cover multiple upper‑abdominal procedures, highlighting its novel table‑integrated design that enables use in space‑constrained operating rooms and reinforces J&J’s commitment to advancing bariatric and general surgery through robotics innovation.
Johnson & Johnson (NYSE:JNJ) focuses on medical robotics and digital surgery. They are actively developing advanced surgical systems and data ecosystems to improve patient outcomes across general surgery, lung diagnostics, and orthopedics.
1. NVIDIA Corporation (NASDAQ:NVDA)
Stock Upside Potential: 44.97%
Forward P/E: 17.3
Number of Hedge Fund Holders: 275
NVIDIA Corporation (NASDAQ:NVDA) is one of the cheap robotics stocks to buy right now. On May 26, NVIDIA Corporation (NASDAQ:NVDA) reported that its Vera CPU met the new CPU requirements for an artificial intelligence factory. Built with fast cores, massive memory bandwidth, and the ability to sustain high performance, the CPU demonstrated sustained high performance when all cores are active.
Consequently, Vera CPU is well-positioned to deliver the throughput factories need to optimize platform power. In addition, it features NVIDIA Olympus CPU cores designed for sequential CPU work underpinning agentic AI, data processing, and orchestration. The CPU is also capable of delivering outstanding performance within the power profile while offering gains across a broad range of workloads.
The competitive edge comes amid Nvidia CEO Jensen Huang’s claim of a $200 billion market for CPUs. The company sees significant long-term demand from China and the US despite the technological tensions. Demand for CPUs is on the rise as companies and businesses gravitate towards agentic AI and the need to perform autonomous functions.
NVIDIA Corporation (NASDAQ:NVDA) focuses on building foundational AI platforms, software, and specialized computer chips to enable physical AI. Rather than building physical robots themselves, they provide the hardware and software systems required for robots to see, learn, perceive their surroundings, and make decisions in real time.
While we acknowledge the potential of NVDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVDA and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Sin Stocks to Buy Now and 8 Best CBD Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
